All In Biotech

NDA 214916 · Vifor Intl

Korsuva

Difelikefalin Acetate · Intravenous

NovelBreakthrough therapyPriority review

CDER novel approval, Aug 23, 2021: To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populations

Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Aug 23, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

22

11 Phase 3, 1 recruiting

FAERS reports

413

297 serious, 64 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 26, 2025.

KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). KORSUVA is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). ( 1 ) Limitation of Use Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population. ( 1 ) Limitations of Use KORSUVA has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.

Mechanism: KORSUVA is a kappa opioid receptor (KOR) agonist. The relevance of KOR activation to therapeutic effectiveness is not known.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 23, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
  • KORSUVA · DIFELIKEFALIN ACETATE EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Difelikefalin" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness45
  • somnolence40
  • fall35
  • death30
  • drug ineffective24
  • mental status changes23
  • confusional state19
  • asthenia18
  • nausea18
  • off label use17
  • pruritus17
  • hallucination16

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202261
2023124
202483
2025102
202643

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Vifor Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.